Andreas Halvorsen's BSX Position Overview
Andreas Halvorsen (via Viking Global Investors Lp) currently holds 2.6M shares of Boston Scientific Corporation (BSX) worth $257.91 M, representing 0.67% of the portfolio. First purchased in 2015-Q3, this long-term strategic position has been held for 41 quarters.
Based on 13F filings since 2013, Andreas Halvorsen has maintained a long-term strategic position in BSX, representing a significant commitment to this investment thesis. Largest addition occurred in Q1 2020, adding 13.3M shares. Largest reduction occurred in Q2 2020, reducing 13.4M shares.
Analysis based on 13F filings available since 2013 Q2
Andreas Halvorsen's Boston Scientific Corporation (BSX) Holding Value Over Time
Track share changes against reported price movement
Quarterly Boston Scientific Corporation (BSX) Trades by Andreas Halvorsen
| Period | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q3 2015 | +1.61 M | New Buy | 1.61 M | $16.41 |
| Q4 2015 | -1.61 M | Sold Out | 1.61 M | $0.00 |
| Q3 2018 | +3.16 M | New Buy | 3.16 M | $38.50 |
| Q4 2018 | +2.05 M | Add 64.82% | 5.2 M | $35.34 |
| Q1 2019 | -1.98 M | Reduce 38.09% | 3.22 M | $38.38 |
| Q2 2019 | +5.97 M | Add 185.53% | 9.2 M | $42.98 |
| Q3 2019 | +1.22 M | Add 13.28% | 10.42 M | $40.69 |
| Q4 2019 | +8.08 M | Add 77.53% | 18.49 M | $45.22 |
| Q1 2020 | +13.32 M | Add 72.06% | 31.82 M | $32.63 |
| Q2 2020 | -13.36 M | Reduce 41.99% | 18.46 M | $35.11 |
| Q3 2020 | +372,457 | Add 2.02% | 18.83 M | $38.21 |
| Q4 2020 | +11.16 M | Add 59.27% | 29.99 M | $35.95 |
| Q1 2021 | -12.09 M | Reduce 40.33% | 17.9 M | $38.65 |
| Q2 2021 | -4.58 M | Reduce 25.59% | 13.32 M | $42.76 |
| Q3 2021 | -6.45 M | Reduce 48.43% | 6.87 M | $43.39 |
| Q4 2021 | +12.1 M | Add 176.15% | 18.96 M | $42.48 |
| Q1 2022 | -6.12 M | Reduce 32.29% | 12.84 M | $44.29 |
| Q2 2022 | +1.81 M | Add 14.13% | 14.65 M | $37.27 |
| Q3 2022 | +1.51 M | Add 10.30% | 16.16 M | $38.73 |
| Q4 2022 | -6.63 M | Reduce 41.05% | 9.53 M | $46.27 |
| Q1 2023 | -8.39 M | Reduce 88.07% | 1.14 M | $50.03 |
| Q2 2023 | -1.14 M | Sold Out | 1.14 M | $0.00 |
| Q3 2023 | +1.11 M | New Buy | 1.11 M | $52.80 |
| Q4 2023 | +1.16 M | Add 104.25% | 2.27 M | $57.81 |
| Q1 2024 | -543,006 | Reduce 23.94% | 1.72 M | $68.49 |
| Q2 2024 | -1.72 M | Sold Out | 1.72 M | $0.00 |
| Q3 2024 | +967,210 | New Buy | 967,210 | $83.80 |
| Q4 2024 | +1.2 M | Add 124.58% | 2.17 M | $89.32 |
| Q1 2025 | +204,556 | Add 9.42% | 2.38 M | $100.88 |
| Q2 2025 | +669,000 | Add 28.15% | 3.05 M | $107.41 |
| Q3 2025 | -404,082 | Reduce 13.27% | 2.64 M | $97.63 |
Andreas Halvorsen's Boston Scientific Corporation Investment FAQs
Andreas Halvorsen first purchased Boston Scientific Corporation (BSX) in Q3 2015, acquiring 1,611,935 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Andreas Halvorsen has held Boston Scientific Corporation (BSX) for 41 quarters since Q3 2015. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Andreas Halvorsen's largest addition to Boston Scientific Corporation (BSX) was in Q1 2020, adding 31,816,197 shares worth $1.04 B. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
According to the latest 13F filing for Q3 2025, Andreas Halvorsen's firm, Viking Global Investors Lp, owns 2,641,682 shares of Boston Scientific Corporation (BSX), valued at approximately $257.91 M. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
As of the Q3 2025 filing, Boston Scientific Corporation (BSX) represents approximately 0.67% of Andreas Halvorsen's publicly disclosed stock portfolio, making it one of their key holdings. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Andreas Halvorsen's peak holding in Boston Scientific Corporation (BSX) was 31,816,197 shares, as reported at the end of Q1 2020. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.